@@ -104,6 +104,20 @@ export function HPFeedback(){
<p>The most common concern, shared by 28.77% of respondents, was related to the safety and side effects of gene therapy, followed by long-term effects (27.85%) and costs or accessibility (24.20%) (see diagram 9). Ethical questions were raised by 14.61% of participants, while only 4.57% had no concerns at all. These concerns echo comments made in other parts of the survey, where respondents expressed interest in learning more about the safety protocols and regulatory measures surrounding gene therapy. Clearly, addressing these concerns in future public engagements will be critical to fostering wider acceptance. </p>
<p>Nearly half (49.59%) of respondents believe that gene therapy represents a major advance in the treatment of diseases, while 47.97% acknowledged that gene therapy offers some progress but also carries risks (see diagram 7). Less than 2% of respondents expressed concern that gene therapy could bring more risks than benefits. This overall positive outlook on gene therapy is encouraging, but it also underscores the need to address concerns about safety and long-term effects, which were often mentioned in the comments. The optimism shown here can be a strong foundation for promoting gene therapy, especially with appropriate education on mitigating risks.</p>
</div>
<divclassName="col">
<Graph.WouldYouDoGeneTherapyPublic/>
<p>A strong majority, 85.22% of respondents, indicated that they would consider opting for gene therapy, with only 1.74% saying they would not, and 13.04% responding with "maybe." (see diagram 8). This result demonstrates considerable openness to gene therapy among the public, though the minority expressing hesitation suggests there are lingering doubts. Comments frequently mentioned concerns over safety and long-term effects, suggesting that these issues need to be addressed to convert "maybe" responses into more confident support for gene therapy.</p>
</div>
<divclassName="col">
<Graph.WhatFormMoreInfoPublic/>
<p>When asked how they would prefer to receive more information, 22.62% of respondents selected TV documentaries and programs as their preferred medium, while 16.63% expressed interest in websites and online resources (see diagram 11). This preference for visual and online formats aligns with the public’s general reliance on media for learning about CF and other medical topics. Social media and online communities (15.96%) also ranked highly, indicating that digital platforms are an effective way to reach a broad audience. These findings can guide future efforts to create engaging and informative content about CF and gene therapy.</p>
